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Key Points




OS (3-year) of
patients with TCL
getting haplo-HCT or
MSD, MUD TCD1, or
MUD TCD2 allo-HCT
was 60%, 63%, 59%,
and 64%,
respectively.
PFS (3-year) of
patients with TCL
getting haplo-HCT or
MSD, MUD TCD1, or
MUD TCD2 allo-HCT
is 50%, 50%, 48%,
and 52%,
respectively.

Mature T-cell lymphomas constitute the most common indication for allogeneic
hematopoietic cell transplantation (allo-HCT) of all lymphomas. Large studies
evaluating contemporary outcomes of allo-HCT in mature T-cell lymphomas relative
to commonly used donor sources are not available. Included in this registry study
were adult patients who had undergone allo-HCT for anaplastic large cell lymphoma,
angioimmunoblastic T-cell lymphoma (AITL), or peripheral T-cell lymphoma not
otherwise speciﬁed (PTCL-NOS) between 2008 and 2018. Hematopoietic cell
transplantation (HCT) platforms compared were posttransplant cyclophosphamidebased haploidentical (haplo-)HCT, matched sibling donor (MSD) HCT, matched
unrelated donor HCT with in vivo T-cell depletion (MUD TCD1), and matched
unrelated donor HCT without in vivo T-cell depletion (MUD TCD2). Coprimary end
points were overall survival (OS) and progression-free survival (PFS); secondary end
points included nonrelapse mortality (NRM), and relapse/progression incidence (RI).
A total of 1942 patients were eligible (237 haplo-HCT; 911 MSD; 468 MUD TCD1; 326
MUD TCD2). Cohorts were comparable for baseline characteristics with the exception
of higher proportions of patients with decreased performance status (PS) and marrow
graft recipients in the haplo-HCT group. Using univariate and multivariate
comparisons, OS, PFS, RI, and NRM were not signiﬁcantly different among the
haplo-HCT, MSD, MUD TCD1, and MUD TCD2 cohorts, with 3-year OS and PFS of
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60%, 63%, 59%, and 64%, respectively, and 50%, 50%, 48%, and 52%, respectively.
Signiﬁcant predictors of inferior OS and PFS on multivariate analysis were active
disease status at HCT and decreased PS. AITL was associated with signiﬁcantly
reduced relapse risk and better PFS compared with PTCL-NOS. Allo-HCT can provide
durable PFS in patients with mature T-cell lymphoma (TCL). Outcomes of haplo-HCT
were comparable to those of matched donor allo-HCT.

on-site audits, and all centers must obtain written informed consent
prior to data registration following the Declaration of Helsinki.

Introduction

With the introduction of posttransplant cyclophosphamide (ptCY)based immunosuppression, allo-HCT using haploidentical related
donors has emerged as a valuable alternative for patients without an
available matched sibling donor (MSD) or matched unrelated donor
(MUD).18 Similar to more common indications for allo-HCT,19-21
ptCY haploidentical (haplo)-HCT seems to provide outcomes comparable to MSD/MUD transplants (using conventional calcineurin
inhibitor [CNI]-based prophylaxis) in patients with lymphoma.22-26
However, these results derive from retrospective analyses of patient
samples with the global diagnoses of Hodgkin lymphoma and/or
NHL. Because of the increasing utilization of allo-HCT in T-NHL, we
evaluated the contemporary outcomes of this modality, relative to
established donor sources, in the three most common nodal variants
of mature T-cell lymphomas (PTCL-NOS, AITL, and ALCL).

Materials and methods
Data sources
The study was performed through collaboration between the European
Society for Blood and Marrow Transplantation (EBMT) and the Center
for International Blood and Marrow Transplant Research (CIBMTR).
EBMT is a voluntary organization comprising .600 transplant centers,
primarily from Europe. Accreditation as a member center requires submission of minimum essential data (MED-A form) from all consecutive
patients to a central registry. Accredited EBMT centers are subject to
8 FEBRUARY 2022 • VOLUME 6, NUMBER 3

CIBMTR is a working group of .380 transplantation centers worldwide that contribute detailed data on hematopoietic cell transplantation (HCT) to a statistical center at the Medical College of Wisconsin.
Participating centers are required to report all transplantations consecutively, patients are followed longitudinally, and compliance is monitored by on-site audits. Computerized checks for discrepancies,
physicians’ review of submitted data, and on-site audits of participating
centers ensure data quality. The CIBMTR collects data at 2 levels:
transplant essential data in all patients and more comprehensive data
(comprehensive report form) in a subset of patients selected by a
weighted randomization scheme. Observational studies conducted by
the CIBMTR are performed in compliance with all applicable federal
regulations pertaining to the protection of human research participants. Patients provided written informed consent for research. The
institutional review boards of the Medical College of Wisconsin and
the National Marrow Donor Program approved this study.

Study design
This was a collaborative retrospective registry-based analysis. Adults
($18 years) with PTCL-NOS, AITL, or ALCL, who had undergone
their ﬁrst allo-HCT between 2008 and 2018, were eligible for the
study. Eligible donors included MSDs, 8 of 8 MUDs (allele-level
match at HLA-A, HLA-B, HLA-C, and HLA-DRB1), or haploidentical
related donors. Recipients of haplo-HCT were limited to those
receiving graft-versus-host disease (GVHD) prophylaxis with ptCY
(with or without CNI and mycophenolate mofetil). GVHD prophylaxis
in MSD recipients was limited to CNI-based approaches without
anti-thymocyte globulin/alemtuzumab in vivo T-cell depletion (TCD),
whereas MUD recipients received CNI-based prophylaxis with or
without in vivo TCD. Patients receiving ex vivo graft manipulation
(eg, CD34 selection; n 5 77) were excluded to reduce study heterogeneity. The CIBMTR cohort was limited to patients from the
United States and Canada to avoid duplicate inclusion of European
patients reported to both registries.

Deﬁnitions
The intensity of allo-HCT conditioning regimens was categorized as
myeloablative conditioning or nonmyeloablative reduced-intensity
conditioning (RIC) using consensus criteria.27 Disease response at
the time of HCT was determined using the current International
Working Group criteria during the time of this analysis.28-30

Study end points
The coprimary end points were overall survival (OS) and
progression-free survival (PFS). Death from any cause was considered an event for OS, and surviving patients were censored at last
follow-up. For PFS, a patient was considered to have failed treatment
ALLOGENEIC HCT FOR MATURE T-NHL
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Mature T-cell lymphomas are a heterogenous group of non-Hodgkin
lymphomas (NHLs) with varied morphological and clinical features1,2
and an overall prognosis that is generally worse than their B-cell counterparts.2 The most common subtypes of mature T-cell lymphoma are
peripheral T-cell lymphoma not otherwise speciﬁed (PTCL-NOS),
angioimmunoblastic T-cell lymphoma (AITL), and anaplastic large cell
lymphoma (ALCL).3 Although the addition of brentuximab vedotin to
anthracycline-based frontline therapies has improved the outcomes of
CD301 T-cell NHL (T-NHL; especially ALCL),4 the results after ﬁrstline treatment of PTCL-NOS and AITL remain suboptimal.5-7 In the
relapsed/refractory setting, available pharmacological options typically
do not provide long-term disease control,8-10 and adoptive immunotherapy in the form of allogeneic hematopoietic cell transplantation
(allo-HCT) remains the only curative option for all 3 subtypes.11-16 In
fact, with the recent decline in allo-HCT utilization for diffuse large
B-cell lymphoma, T-NHL now constitutes the most common indication
for allo-HCT for lymphomas in the United States and Europe.17 Historically, application of this option (even in relatively younger patients) was
limited by the lack of donor availability and high procedure-related mortality rates (30% to 35% at 1 year).11-13 Large contemporary analyses evaluating outcomes after allo-HCT in mature T-NHL, especially
relative to alternative donor sources, are not available.

Statistical analysis
The haplo-HCT cohort was compared against the MSD, MUD with
TCD (MUD TCD1), and MUD without TCD (MUD TCD2) cohorts.
Patient-, disease- and transplant-related variables were compared
among the 4 cohorts using the x2 test for categorical variables and
the Mann-Whitney U test for continuous variables. Cumulative incidences of hematopoietic recovery, acute and chronic GVHD,
relapse, and NRM were calculated to accommodate for competing
risks.
Associations among patient-, disease, and transplantation-related
variables and outcomes of interest were evaluated using Cox
proportional-hazards regression for acute GVHD, chronic GVHD,
relapse, NRM, PFS, and OS. All potential prognostic factors for outcomes and characteristics that differed among the groups were
included in multivariate models (stratiﬁed on data source [CIBMTR
vs EBMT]): donor source, disease status at HCT, patient age,
patient sex, cell source, conditioning regimen intensity, prior autologous HCT, Karnofsky Performance Status (KPS), and histology. The
proportional hazards assumption for Cox regression was tested by
adding a time-dependent covariate for each risk factor and each
outcome. Covariates violating the proportional hazards assumption
were added as time-dependent covariates in the Cox regression
model. Interactions between the main effect and signiﬁcant covariates were examined. All tests were 2 sided. The type I error rate
was ﬁxed at 0.05. Statistical analyses were performed with SPSS
26 (SPSS Inc., Chicago, IL), and R 3.6.1 (R Development Core
Team, Vienna, Austria) software packages.

note, patients receiving haplo-HCT were excluded from both of
these studies. There were no signiﬁcant differences among the 4
cohorts in terms of patient sex, disease status at allo-HCT, HCTcomorbidity index, median number of prior therapies, distribution of
T-cell histologies, and history of autologous HCT. Compared with
the MSD and MUD cohorts, patients in the haplo-HCT cohort more
frequently had a KPS # 90 (42% vs 32-35%; P 5 .03) and bone
marrow as graft source (31% vs 6-7%; P , .001). Use of RIC was
more frequent in the haplo-HCT (73%) and MUD TCD2 (73%)
cohorts compared with the MSD (62%) and MUD TCD1 (67%)
cohorts (P , .001). Fewer patients in the MSD cohort were $60
years of age (19%) compared with other cohorts (26-29%). Details
are given in Table 1. The completeness of patient follow-up at 1
year, 2 years, and 3 years was 94.5%, 86.5%, and 79.2%,
respectively.

Hematopoietic recovery
The day-28 cumulative incidence of neutrophil recovery was signiﬁcantly lower in the haplo-HCT cohort (86%; 95% conﬁdence interval [CI], 81-90) compared with the MSD (95%; 95% CI, 94-97),
MUD TCD1 (94%; 95% CI, 91-96), and MUD TCD2 (97%; 95%
CI, 94-98) cohorts (P , .001; Table 2; supplemental Figure 1).
Similarly, the day-100 cumulative incidence of platelet recovery was
signiﬁcantly lower in the haplo-HCT cohort (80%; 95% CI, 74-85)
compared with the MSD (96%; 95% CI, 94-97), MUD TCD1
(93%; 95% CI, 89-95) and MUD TCD2 (96%; 95% CI, 93-98)
cohorts (P , .001; Table 2; supplemental Figure 1).

GVHD
The day-100 cumulative incidence of acute GVHD grade 2-4 (grade
3-4) in the haplo-HCT, MSD, MUD TCD1, and MUD TCD2
cohorts was 33% (9%), 31% (11%), 30% (10%), and 37%
(18%), respectively (Table 2). Using multivariate analysis, compared
with haplo-HCT, the MUD TCD2 cohort was associated with a signiﬁcantly higher risk for grade 3-4 acute GVHD (hazard ratio [HR],
2.0; 95% CI, 1.2-3.3; P 5 .01) (Table 3). The 1-year cumulative
incidence of chronic GVHD in the haplo-HCT, MSD, MUD TCD1,
and MUD TCD2 cohorts was 28%, 41%, 35%, and 54%, respectively (Table 2). Using multivariate analysis, compared with haploHCT, the MSD (HR, 1.7; 95% CI, 1.3-2.2; P , .001), MUD TCD1
(HR, 1.4; 95% CI, 1.0-1.9; P 5 .047), and MUD TCD2 (HR, 2.4;
95% CI, 1.8-3.2; P , .001) cohorts were associated with a signiﬁcantly higher risk for chronic GVHD (Figure 1A; Table 3).

NRM

Results

The 3-year cumulative incidence of NRM in the haplo-HCT, MSD,
MUD TCD1, and MUD TCD2 cohorts was 22%, 21%, 24%, and
23%, respectively (Figure 1B; Table 2). The risk of NRM was not
signiﬁcantly different among the 4 cohorts on multivariate analysis
(Table 3). Resistant disease at HCT, age $ 40 years, and KPS , 90
were independently associated with a higher risk for NRM (Table 3).

Patient and transplant characteristics

Disease control

Altogether, 1942 eligible patients (haplo-HCT, n 5 237; MSD,
n 5 911; MUD TCD1, n 5 468; MUD TCD2, n 5 326) were
included. Of these, 23 patients were part of a previous EBMT study
addressing the outcome of allo-HCT in ALCL,34 and 144 patients
overlapped with a prior CIBMTR analysis of allo-HCT in AITL.35 Of

The 3-year cumulative incidence of relapse/progression was 28%
(95% CI, 22-35) in the haplo-HCT cohort compared with 29%,
28%, and 25% in the MSD, MUD TCD1, and MUD TCD2 cohorts,
respectively (Figure 1C; Table 2). The risk of relapse/progression
was not signiﬁcantly different among the 4 cohorts on multivariate
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at the time of progression/relapse or death from any cause. Patients
alive without evidence of disease relapse or progression were censored at last follow-up. Secondary outcomes included nonrelapse
mortality (NRM) and progression/relapse. NRM was deﬁned as
death without evidence of prior lymphoma progression/relapse;
relapse was considered a competing risk. Progression/relapse was
deﬁned as progressive lymphoma after HCT or lymphoma recurrence after a complete remission (CR); NRM was considered a competing risk. Acute GVHD and chronic GVHD were graded using
established clinical criteria.31,32 GVHD-free relapse-free survival
(GRFS) was calculated using the modiﬁcation proposed by Ruggeri
et al for registry-based studies).33 Probabilities of GRFS, PFS, and
OS were calculated using Kaplan-Meier estimates. Neutrophil recovery was deﬁned as the ﬁrst of 3 successive days with absolute neutrophil count $ 500 per microliter after the posttransplantation nadir.
Platelet recovery was considered to have occurred on the ﬁrst of 3
consecutive days with platelet count $ 20 000 per microliter, in the
absence of platelet transfusion for 7 consecutive days. For neutrophil
and platelet recovery, death without the event was considered a
competing risk.

Table 1. Patient characteristics
Haplo-HCT

MSD HCT

MUD TCD1

MUD TCD2

237

911

468

326

CIBMTR

104 (44)

324 (36)

156 (33)

209 (64)

EBMT

133 (56)

587 (64)

312 (67)

117 (36)

Patients, n

P

,.001

Data source

Age, y
Median, range

54 (18-76)

60-69

51 (21)

$70

11 (5)

8 (1)

53 (18-75)
126 (27)

54 (18-74)

.004

89 (27)

10 (2)

6 (2)

84 (35)

322 (35)

165 (35)

119 (37)

.98

131 (58)

584 (68)

301 (68)

209 (65)

.03

10

47

KPS
$90
Not reported

24

5
,.001

Cell source
Bone marrow

74 (31)

61 (7)

26 (6)

23 (7)

163 (69)

850 (93)

442 (94)

303 (93)

65 (27)

345 (38)

154 (33)

86 (27)

172 (73)

552 (62)

306 (67)

239 (73)

0

14

CR

120 (51)

451 (51)

238 (52)

161 (51)

PR

74 (32)

252 (29)

124 (27)

96 (30)

Resistant/Untreated

39 (17)

177 (20)

93 (20)

60 (19)

Peripheral blood

,.001

Conditioning intensity
Myeloablative
RIC
Missing data

8

1
.84

Disease status

Missing data

4

31

13

9

HCT-CI
$3

52 (28)

Missing data*

191 (30)

52

280

105 (35)

95 (37)

164

.08

72

Chemotherapy lines
Median (IQR), n

2 (1-3)

2 (1-3)

2 (2-3)

1 line†

31 (23)

2 (1.8-3)

89 (26)

57 (29)

19 (21)

2 lines†

47 (34)

109 (32)

62 (32)

32 (34)

$3 lines†

58 (43)

143 (42)

76 (39)

42 (45)

Missing data‡

101

Female donor/male recipient

570

273

.34

233

61 (26)

254 (28)

52 (11)

45 (14)

68 (29)

270 (30)

155 (33)

101 (31)

ALCL§

58 (24)

170 (19)

82 (18)

75 (23)

PTCL

111 (47)

471 (51)

231 (49)

150 (46)

,.001
.14

Histology
AITL

Prior autologous HCT

78 (33)

Follow-up, median (range) [IQR], months

24 (1-113) [13-48]

336 (37)
43 (1-128) [17-72]

195 (42)

132 (41)

35 (1-132) [13-63]

.09

49 (1-134) [24-72]

Unless otherwise noted, data are n (%).
HCT-CI, HCT-comorbidity index; IQR, interquartile range; PR, partial response; PTCL, peripheral T-cell lymphoma.
*EBMT does not collect this variable for Minimum Essential Data – A patients.
†Missing number was excluded when calculating percentages.
‡CIBMTR does not collect this variable for the transplant-essential level patients.
§ALCLs included 116 ALK1 cases, 143 ALK2 cases, and 126 cases for which ALK status was not known.

analysis (Table 3). Other factors independently associated with the
risk of relapse included disease status at HCT, female donor for
male recipient, KPS, and lymphoma subtype (Table 3). Across all 4
8 FEBRUARY 2022 • VOLUME 6, NUMBER 3

donor groups, the majority of relapse/progression events occurred
within the ﬁrst 6 months after allo-HCT, whereas events became
rare beyond 2 years post-HCT.
ALLOGENEIC HCT FOR MATURE T-NHL
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Males

51 (18-77)
164 (18)

Table 2. Univariate outcomes
Outcomes

Haplo-HCT
(N 5 235)

MSD HCT
(N 5 909)

MUD TCD1
(N 5 465)

MUD TCD2
(N 5 325)

P

Neutrophil recovery, 28 d

n 5 230

86 (81-90)

n 5 883

95 (94-97)

n 5 453

94 (91-96)

n 5 322

97 (94-98)

,.001

Platelet recovery, 100 d

n 5 219

80 (74-85)

n 5 737

96 (94-97)

n 5 378

93 (89-95)

n 5 284

96 (93-98)

,.001

Stage II-IV acute GVHD, 100 d

n 5 225

33 (27-39)

n 5 837

31 (28-34)

n 5 429

30 (26-35)

n 5 305

37 (32-42)

.03

Stage III-IV acute GVHD, 100 d

n 5 225

9 (6-13)

n 5 837

11 (9-13)

n 5 429

10 (8-13)

n 5 305

18 (14-23)

Chronic GVHD

n 5 226

n 5 770

n 5 395

n 5 296

1-y

28 (22-34)

41 (37-44)

35 (30-40)

2-y

32 (25-38)

50 (47-54)

41 (36-46)

n 5 237

NRM

n 5 911

n 5 468

54 (48-59)
64 (58-70)
n 5 326

.49

11 (7-16)

8 (7-10)

10 (8-13)

8 (6-12)

1y

20 (15-25)

15 (13-18)

18 (15-22)

16 (13-21)

3y

22 (17-28)

21 (18-23)

24 (20-28)

n 5 237

n 5 911

n 5 468

23 (18-28)
n 5 326

.73

1y

22 (17-28)

25 (22-27)

23 (19-27)

23 (19-28)

2y

27 (21-33)

29 (25-32)

26 (22-31)

25 (20-30)

3y

28 (22-35)

29 (26-32)

28 (24-33)

n 5 235

PFS

n 5 909

n 5 465

25 (21-30)
n 5 325

.80

1y

59 (52-65)

61 (57-64)

59 (54-63)

60 (55-65)

3y

50 (43-57)

50 (47-54)

48 (43-53)

52 (46-58)

n 5 237

OS
1y

n 5 911
70 (63-75)

3y

60 (52-66)

GRFS

n 5 179

n 5 468
74 (71-77)
63 (59-66)

n 5 665

n 5 326
70 (65-74)
59 (54-64)

n 5 378

.30
74 (69-78)
64 (58-69)

n 5 210

.02

1y

46 (38-53)

46 (42-50)

50 (44-55)

38 (32-45)

2y

37 (29-45)

36 (32-40)

41 (36-46)

31 (25-37)

Unless otherwise noted, all data are probability, % (95% conﬁdence interval).

Survival
The median follow-up of survivors was 38 months (range, 1-134). The
3-year PFS in the haplo-HCT group was 50% (95% CI, 52-66) compared with 50%, 48%, and 52% in the MSD, MUD TCD1, and
MUD TCD2 cohorts, respectively (Figure 1D; Table 2). The 3-year
OS was 60%, 63%, 59%, and 64%, respectively (Figure 1F; Table
2). Multivariate analyses did not reveal a signiﬁcant difference in OS or
PFS among the 4 cohorts (Table 3). Disease status less than a CR,
age $ 40 years, and decreased KPS signiﬁcantly reduced OS and
PFS on multivariate analysis. In addition, PFS was signiﬁcantly associated with AITL histology and donor-recipient sex mismatch (Table 3).
Table 4 summarizes allo-HCT univariate outcomes based on pretransplant remission status. The 3-year PFS for patients in CR or partial
remission, as well as for those with refractory/untreated relapse, was
57%, 47%, and 36% respectively (P , .0001). The respective 3-year
OS estimates were 68%, 59%, and 49% (P , .0001).
Two-year composite end point GRFS following haplo-HCT was
37% (95% CI, 29-45) compared with 36% (95% CI, 32-40) following MSD, 41% (95% CI, 36-46) following MUD TCD1, and 31%
(95% CI, 25-37) following MUD TCD2 (P 5 .02; Figure 1F).

footnote †). Baseline characteristics and univariate analysis outcomes for patients with data available for prior therapy lines are
shown in supplemental Tables 1 and 2). To adjust for confounding
variables, the impact of the number of treatment lines prior to alloHCT was examined in a separate exploratory multivariate model
restricted to patients with available data (supplemental Table 3).
More than 1 treatment line prior to allo-HCT was associated with a
signiﬁcantly higher risk for NRM (HR, 1.8; P 5 .02) but not relapse/
progression or PFS. Patients receiving $3 treatment lines prior to
allo-HCT also had a higher risk for overall mortality (HR, 1.6; P 5
.02).

Causes of death
The most common cause of death in all 4 cohorts was recurrent
T-NHL (haplo-HCT, 38%; MSD, 36%; MUD TCD1, 30%; MUD
TCD2, 31%). Overall, infections accounted for the second most
common cause of death (19%), with the numerically highest proportion in the MUD TCD1 group (22%), followed by the haplo-HCT
(20%), MUD TCD2 (19%), and MSD (17%) groups (supplemental
Table 4).

Subgroup analysis

Discussion

Information about the number of therapy lines prior to allo-HCT was
not available for 1177 patients (61%; explained in Table 1,

Allo-HCT is an effective form of adoptive immunotherapy for patients
with high-risk and/or relapsed/refractory T-NHL. Although mature
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100 d

Relapse

.002
,.001

Table 3. Multivariate analysis
OS

PFS

Relapse

Acute GVHD
stage III-IV

NRM

Chronic
GVHD

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

0.9 (0.7-1.2)

.42

1.0 (0.8-1.2)

.75

1.0 (0.8-1.4)

.89

0.9 (0.7-1.3)

.60

1.2 (0.8-2)

MUD TCD1

0.9 (0.7-1.3)

.70

1.0 (0.8-1.3)

.76

1.1 (0.8-1.5)

.54

1.0 (0.7-1.4)

.94

1.0 (0.5-1.7)

.88

1.4 (1-1.9)

MUD TCD2

0.9 (0.7-1.2)

.40

0.9 (0.7-1.2)

.71

0.9 (0.6-1.2)

.41

1.0 (0.7-1.5)

.83

2.0 (1.2-3.3)

.01

2.4 (1.8-3.2)

1.4 (1.1-1.6)

.001

1.4 (1.2-1.7)

<.001

1.7 (1.4-2.1)

<.001

1.2 (0.9-1.5)

.12

1.2 (0.9-1.7)

.280 1.1 (0.9-1.3)

.25

1.8 (1.4-2.1)

<.001

1.9 (1.6-2.2)

<.001

2.4 (1.9-3)

<.001

1.5 (1.2-2)

.001

1.8 (1.3-2.6)

.001 1.2 (0.9-1.4)

.19

Covariates

Reference group *

HR (95% CI)

HR (95% CI)

P

HR (95% CI)

P

.39

1.7 (1.3-2.2)

<.001

Type of donor
MSD

Haplo-HCT

.047
<.001

Disease status
PR

CR

Resistant/Unt

40-59

18-39

$60
Sex

.01

1.7 (1.3-2.2)

<.001

1.2 (1-1.5)

.04

1.0 (0.8-1.3)

.75

1.6 (1.2-2.3)

.005

1.2 (0.8-1.8)

.37

1.3 (1.1-1.6)

.01

1.4 (1.1-1.7)

.007

1.0 (0.7-1.3)

.95

2.1 (1.5-3.1)

<.001

1.4 (0.9-2.3)

.11

1.3 (1.1-1.7)

.02

0.9 (0.7-1)

.09

0.9 (0.8-1)

.15

0.9 (0.7-1)

.12

0.9 (0.7-1.2)

.60

0.7 (0.5-0.9)

.01

Yes vs no

1.1 (0.9-1.3)

.50

1.2 (1-1.4)

.045

1.3 (1-1.6)

.03

1.1 (0.9-1.5)

.38

0.9 (0.6-1.3)

.64

1.4 (1.1-1.7)

Cell source

PB vs BM

0.9 (0.7-1.2)

.63

0.9 (0.7-1.1)

.25

0.8 (0.6-1.2)

.29

0.8 (0.6-1.2)

.27

1.1 (0.6-1.8)

.79

0.9 (0.7-1.2)

.62

Conditioning

RIC vs MAC

1 (0.9-1.2)

.63

1.1 (0.9-1.2)

.47

1.2 (0.9-1.4)

.15

1.0 (0.8-1.2)

.80

1 (0.8-1.4)

.87

1 (0.9-1.2)

.99

Female donor/male
recipient

Prior auto-HCT
KPS

Female vs male

1.3 (1.1-1.7)

.90

1.1 (0.9-1.2)

.40

,90 vs 90

Yes vs no

1.5 (1.3-1.8)

1 (0.8-1.2)

<.001

1.3 (1.2-1.5)

<.001

PTCL

0.9 (0.8-1.2)

.59

1.1 (0.9-1.3)

.31

0.9 (0.7-1)

.09

0.7 (0.6-0.9)

<.001

1 (0.8-1.2)

1 (0.86-1.2)

.88
.001

.850

1.1 (0.9-1.4)

.29

0.8 (0.6-1)

.08

1 (0.9-1.2)

.60

.02

1.4 (1.2-1.8)

.001

1.2 (0.9-1.6)

.25

0.9 (0.8-1.1)

.28

1.3 (1.1-1.6)

.01

0.8 (0.6-1.1)

.19

1.5 (1.1-2.2)

.02

1.1 (0.9-1.4)

.23

0.5 (0.4-0.7)

<.001

0.9 (0.8-1.2)

.52

1.1 (0.8-1.5)

.63

1.0 (0.8-1.2)

.86

1.3 (1-1.5)

Histology
ALCL
AITL

Auto, autologous; BM, bone marrow; MAC, myeloablative conditioning; PB, peripheral blood; PTCL, peripheral T-cell lymphoma; PR, partial remission; Unt, untreated.
Statistically signiﬁcant P values are shown in bold type.
*Reference group is in bold type.

T-cell neoplasms now constitute the most common lymphoma indication for allografting in the United States and Europe,17 published
studies of allo-HCT in T-cell lymphoma have been limited by small
sample size and the heterogeneity of underlying diagnoses and
largely refer to transplant series performed in the early 2000s.36 In
contrast, this joint analysis performed by the EBMT and the
CIBMTR evaluated a 15-fold larger sample than the prior registry
study,12 focuses on the 3 most important T-NHL entities, and covers a contemporary era with speciﬁc emphasis on haplo-HCT. Several important observations were made: (1) regardless of the donor
source, allo-HCT provides unprecedented rates of survival outcomes (3-year OS, 60-64%; PFS, 48-52%), (2) disease recurrence
appears to be a rare event for patients surviving 2 years relapse
free, (3) careful patient preparation (eg, adequate disease control,
patient ﬁtness) remains a crucial factor that impacts allo-HCT outcomes, and (4) the efﬁcacy of allo-HCT appears to differ among the
3 main T-NHL subsets, with the lowest risk of relapse in AITL.
The current collaborative analysis highlights the remarkable improvements in the outcomes of allo-HCT for T-NHL since the last
CIBMTR analysis looking at a similar population.12 That study reporting allo-HCT outcomes in PTCL-NOS, AITL, and ALCL (between
1996 and 2006) was notably restricted to younger patients
(age # 60 years) receiving HLA-matched allografts.12 In that analysis, the 3-year rates for PFS and OS were 37% and 46%, respectively, and NRM rates ranged from 27% to 34%, depending on
conditioning intensity. By contrast, in our study reﬂecting the period
between 2008 and 2018, the 3-year NRM, PFS, and OS are
8 FEBRUARY 2022 • VOLUME 6, NUMBER 3

substantially better (20%, 50%, and 60%, respectively), despite
inclusion of alternative donor sources and that a sizable proportion
of patients were $60 years of age (n 5 465; 24%). These
improved outcomes are potentially due to advances in unrelated
donor selection, transplant supportive care, and management of
posttransplant complications.
The outcomes of the haplo-HCT cohort in our study (n 5 237) also
validate the results of prior retrospective studies limited by small
sample sizes (n 5 20-35 patients), the broad variety of T-NHL subtypes investigated, and restriction to single-center analyses and/or
certain types of conditioning and graft sources (n # 35).37-40 Thus,
this study is the ﬁrst one to show comparable outcomes after haploHCT and matched donor transplants across the 3 main T-cell lymphoma subsets using a reasonable patient number in a multicenter
setting. Based on the current analysis, we cannot speculate about
scenarios in which haplo-HCT might be preferable over matched
donor HCT and vice versa. However, in a recent cross-sectional
EBMT study of predictors of haplo-HCT outcomes in lymphoma,
chemorefractoriness at transplantation and primary diagnosis
emerged as the only signiﬁcant independent risk factors for
survival.41
The timing of allo-HCT in T-NHL is controversial (in ﬁrst remission
vs for relapsed/refractory disease). A French/German randomized
study compared allo-HCT with autologous HCT in younger patients
with nodal T-cell lymphoma as part of ﬁrst-line therapy.15 Roughly
half of the patients randomized to allo-HCT (23/49) did not undergo
ALLOGENEIC HCT FOR MATURE T-NHL
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Patient age, y

A

B

C

Chronic GVHD

Non-relapse mortality

Cumulative incidence, %

100

Relapse

100

100

p0.001

p=0.49

p=0.7

80

80

80

60

60

60

40

40

40

20

20

20

0

0
1

2

0
0

1

2

Years

3

0

1

Years

2

3

Years

Haplo 226

89

53

Haplo 237

117

73

53

Haplo 237

117

73

53

HLA sibling 770

314

184

HLA sibling 911

482

351

278

HLA sibling 911

482

351

278

MU no ATG 296

81

43

MU no ATG 326

181

148

117

MU no ATG 326

181

148

117

MU w/ ATG 395

172

109

MU w/ ATG 468

234

164

126

MU w/ ATG 468

234

164

126

D

E

F
Overall survival

Progression-free survival
100

100

p=0.8

Probability, %

GRFS

100

p=0.02

p=0.3

80

80

80

60

60

60

40

40

40

20

20

20

0

0
0

1

2

3

0
0

1

2

Years

0

3

Years

1

2

Years

Haplo 235

117

73

53

Haplo 235

140

89

64

Haplo 179

69

39

HLA sibling 909

482

351

278

HLA sibling 900

593

451

353

HLA sibling 665

263

168

MU no ATG 325

181

148

117

MU no ATG 326

223

181

141

MU no ATG 210

72

52

MU w/ ATG 465

234

164

126

MU w/ ATG 465

279

201

152

MU w/ ATG 378

162

105

Haplo

HLA sibling

MUD no ATG

MUD w/ ATG

Figure 1. Transplantation outcomes. Cumulative incidence of chronic GVHD (A), NRM (B) and relapse (C). Probability of PFS (D), OS (E), and GRFS (F). ATG,
anti-thymocyte globulin; Haplo, haplo-HCT; MU, matched unrelated donor.

allotransplantation, largely because of disease progression and
donor unavailability. No difference in survival outcomes was seen
among the 67 patients undergoing HCT. At this time, the American
Society for Transplantation and Cellular Therapy guidelines do not
recommend allo-HCT in ﬁrst CR for nodal mature T-NHL.42 Notably,
although our study suggests that survival after allo-HCT decreases
with an increasing number of pretreatment lines, this effect reached
statistical signiﬁcance only in cases with $3 lines of therapy, but
not if 1 vs 2 prior lines of treatment were compared. However, the
design of our study does not permit valid conclusions about the
impact of early vs delayed allo-HCT on the natural course of T-NHL.
This study represents the ﬁrst time that it was possible to compare
allo-HCT outcomes of the main T-NHL subsets using an informative
sample size. Relative to PTCL-NOS, patients with AITL had a signiﬁcantly lower risk for relapse and better PFS (Table 3). This is in
keeping with preliminary data suggesting that AITL appears to be
exquisitely sensitive to graft-versus-leukemia effects43 and with a
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previous CIBMTR study showing excellent survival of patients with
AITL after RIC allo-HCT (4-year survival, 70%) and no relapses
beyond 2 years.35 On the other hand, patients with ALCL had a signiﬁcantly higher risk of relapse relative to PTCL-NOS (Table 3),
which is in accordance with a previous small EBMT series also containing mismatched unrelated donors in which a 3-year relapse incidence of 40% was observed.34 The beneﬁts of intensifying
conditioning intensity in patients with lymphoma are debatable. Inline
with previous studies on allo-HCT in other NHL subtypes,22,35,44-48
this study does not show an advantage for high-intensity conditioning regimens for the ﬁrst time also for mature nodal T-NHL in a large
data set.
Disease status at HCT was an independent outcome predictor in
our analysis. Although being in CR at transplant was most favorable,
patients in partial remission experienced 3-year PFS and OS of
47% and 58%, respectively, which seems to suggest that alloHCT can provide durable disease control in a sizeable subset of
8 FEBRUARY 2022 • VOLUME 6, NUMBER 3
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Table 4. Univariate outcomes according to preallogeneic transplant remission status

At 1 y

At 3 y

OS

PFS

Relapse/progression

NRM

CR

79 (76-82)

68 (65-71)

17 (15-20)

15 (13-17)

Partial remission

70 (66-74)

55 (51-59)

29 (25-33)

16 (13-19)

Resistant/untreated

61 (55-65)

45 (39-50)

34 (29-39)

21 (17-26)

P

,.0001

,.0001

,.0001

.13

CR

68 (65-71)

57 (53-60)

22 (19-25)

21 (19-24)

Partial remission

59 (54-63)

47 (42-51)

33 (29-37)

20 (17-24)

Resistant/untreated

49 (4455)

36 (31-41)

39 (33-44)

25 (21-30)

P

,.0001

,0001

,.0001

.13

responding patients not in CR. Outcomes are not as encouraging in
resistant disease, but 3-year PFS (36%) and OS (49%) still appear
to be very reasonable for patients with refractory T-NHL.
Unlike their B-cell counterparts, chimeric antigen receptor (CAR)
T-cell therapies for T-cell lymphoma are in the early phases of development. Inherent challenges of CARs for T-cell malignancies include
fratricide by self-targeting of antigens on the CARs themselves and
a high risk of life-threatening infections due to potential T-cell aplasia. Several antigens under active investigation include CD5, CD7,
CD30, CD3, CD4, and T-cell receptor b-chain constant region,
among others.17 Future studies will deﬁne the safety and efﬁcacy
proﬁle of CAR platforms in T-cell malignancies. Until then, allo-HCT
remains a standard-of-care option for the management of relapsed/
refractory mature T-NHL.
When interpreting the results of our study, some important shortcomings inherent to its design need to be considered. There are
signiﬁcant differences to consider between the patients who underwent haplo-HCT and the other groups. The haplo-HCT cohort had
more patients with KPS , 90, and bone marrow grafts and RIC
were used more frequently. Most importantly, GVHD prophylaxis
was inherently different among the groups. Application of the ptCY
platform to MUD transplants may question the equivalence of haploHCT and matched donor transplantation.49 This analysis is underpowered to detect small differences among the cohorts. The typical
limitations of a registry analysis have to be taken into account, such
as selection bias (ie, applicable only to ﬁtter patients in remission
who are able to undergo HCT), lack of central review of histology,
unavailability of ALK status for one third of patients with ALCL
(Table 2, footnote #3), and missing information on other confounders that could not be compensated for (eg, center practices and
patient selection). In addition, during the era of this analysis the registries did not collect information on imaging modalities used for
response assessment (computed tomography scan or positron
emission tomography scan) or captured data regarding postrelapse
therapies.
In summary, this study shows that, in the modern era, adoptive
immunotherapy using allo-HCT can provide high rates of durable
disease control in high-risk nodal mature T-cell lymphomas, with
NRM rates that compare favorably against historical data. Outcomes
are comparable across various commonly used donor sources in
the contemporary era. Early evaluation by transplant physicians
should be considered in all patients with refractory or relapsed
nodal mature T-cell lymphomas.
8 FEBRUARY 2022 • VOLUME 6, NUMBER 3
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